Mission Wealth Management LP Sells 6,642 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mission Wealth Management LP lowered its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 12.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 46,912 shares of the medical research company's stock after selling 6,642 shares during the quarter. Mission Wealth Management LP's holdings in Edwards Lifesciences were worth $3,473,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in EW. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. State Street Corp lifted its holdings in shares of Edwards Lifesciences by 1.0% in the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company's stock worth $1,733,270,000 after buying an additional 256,538 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company's stock valued at $889,050,000 after acquiring an additional 284,918 shares during the period. Fisher Asset Management LLC grew its stake in Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after acquiring an additional 696,965 shares in the last quarter. Finally, Jennison Associates LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth approximately $555,939,000. 79.46% of the stock is currently owned by institutional investors.

Remove Ads

Edwards Lifesciences Stock Down 1.5 %

Shares of NYSE:EW traded down $1.06 during trading on Thursday, hitting $71.79. The stock had a trading volume of 5,028,664 shares, compared to its average volume of 4,486,153. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a market capitalization of $42.34 billion, a PE ratio of 10.30, a PEG ratio of 4.82 and a beta of 1.10. The firm's fifty day moving average is $72.45 and its 200 day moving average is $70.35.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of recent analyst reports. Citigroup boosted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a report on Thursday, February 13th. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Finally, Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $82.00 to $90.00 in a report on Monday, December 16th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $79.95.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of the firm's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company's stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the transaction, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,739 shares of company stock worth $2,799,104 in the last 90 days. Insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.